SALSALATE SODIUM

US Previously Marketed

First approved in 1995

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H9O5.Na
Molecular Weight	280.208
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].OC1=CC=CC=C1C(=O)OC2=CC=CC=C2C([O-])=O

InChI

InChIKey=JOCPDKGMOXSKRO-UHFFFAOYSA-M

InChI=1S/C14H10O5.Na/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17;/h1-8,15H,(H,16,17);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H9O5
Molecular Weight	257.2183
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/salsalate.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23817699 | https://www.ncbi.nlm.nih.gov/pubmed/6520777

Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23 Target ID: GO:0001516 Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 320 Sources: http://www.rxlist.com/disalcid-drug/indications-dosage.htm	Palliative	Approved 8583	DISALCID Approved Use Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder.
Osteoarthritis 157 Sources: http://www.rxlist.com/disalcid-drug/indications-dosage.htm	Palliative	Approved 8583	DISALCID Approved Use Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
Type 2 diabetes mellitus 262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23817699	Primary	Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
45 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
88 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
97 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7309902/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
54.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7309902/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
101 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
50 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
847 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1301 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
50 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7309902/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
498 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7309902/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3956057/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7309902/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	SALSALATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7309902/	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	SALICYLIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% OTHER https://www.pdr.net/drug-summary/Salsalate-salsalate-1649#16			SALICYLIC ACID serum	Homo sapiens

Doses

Dose	Population	Adverse events
1.5 g 3 times / day multiple, oral Higher than recommended Dose: 1.5 g, 3 times / day Route: oral Route: multiple Dose: 1.5 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	Disc. AE: Tinnitus, Headache... Other AEs: Tinnitus... AEs leading to discontinuation/dose reduction: Tinnitus (14.3%) Headache (14.3%) Other AEs: Tinnitus (85.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/
2 g 2 times / day multiple, oral MTD Dose: 2 g, 2 times / day Route: oral Route: multiple Dose: 2 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	Disc. AE: Tinnitus... AEs leading to discontinuation/dose reduction: Tinnitus (37.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/
1.5 g 2 times / day multiple, oral Recommended Dose: 1.5 g, 2 times / day Route: oral Route: multiple Dose: 1.5 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/	Disc. AE: Gastro-intestinal disorder NOS, Tinnitus... AEs leading to discontinuation/dose reduction: Gastro-intestinal disorder NOS (13.2%) Tinnitus (6.7%) Dizziness (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/

AEs

AE	Significance	Dose	Population
Headache	14.3% Disc. AE	1.5 g 3 times / day multiple, oral Higher than recommended Dose: 1.5 g, 3 times / day Route: oral Route: multiple Dose: 1.5 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/
Tinnitus	14.3% Disc. AE	1.5 g 3 times / day multiple, oral Higher than recommended Dose: 1.5 g, 3 times / day Route: oral Route: multiple Dose: 1.5 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/
Tinnitus	85.7%	1.5 g 3 times / day multiple, oral Higher than recommended Dose: 1.5 g, 3 times / day Route: oral Route: multiple Dose: 1.5 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/
Tinnitus	37.5% Disc. AE	2 g 2 times / day multiple, oral MTD Dose: 2 g, 2 times / day Route: oral Route: multiple Dose: 2 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19337387/
Dizziness	1.7% Disc. AE	1.5 g 2 times / day multiple, oral Recommended Dose: 1.5 g, 2 times / day Route: oral Route: multiple Dose: 1.5 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/
Gastro-intestinal disorder NOS	13.2% Disc. AE	1.5 g 2 times / day multiple, oral Recommended Dose: 1.5 g, 2 times / day Route: oral Route: multiple Dose: 1.5 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/
Tinnitus	6.7% Disc. AE	1.5 g 2 times / day multiple, oral Recommended Dose: 1.5 g, 2 times / day Route: oral Route: multiple Dose: 1.5 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8595635/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP2E1 1060 BSEP 550 CYP1A2 2153 CYP2C19 2057 CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1NDExMSJ9fQ==	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1NDExMSJ9fQ==	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1NDExMSJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1NDExMSJ9fQ==	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTU0MTExIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1NDExMSJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTU0MTExIn19	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1NDExMSJ9fQ==	no [IC50 >1000 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5161#section=BioAssay-Results Page: 153.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5161#section=BioAssay-Results Page: 200.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5161#section=BioAssay-Results Page: 198 \| 200	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTU0MTExIn19

PubMed

Title	Date	PubMed
Modulation of endothelial cell activation in sickle cell disease: a pilot study.	2001 Apr 1	11264155
Lichenoid drug eruption to salsalate.	2001 Oct	11568758
Blood pressure elevation in a patient treated with salsalate.	2002 Apr	11918510
Interaction of rofecoxib and celecoxib with warfarin.	2003 Jul 1	12901032
Aspirin and NSAID sensitivity.	2004 Aug	15242723
Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells.	2005 Jan-Feb	15796154
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.	2006	16808554
Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.	2006 Sep	16880431
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle.	2008 Aug	18443205
Salsalate improves glycemia and inflammatory parameters in obese young adults.	2008 Feb	17959861
Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes.	2008 Jul	18594064
Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study.	2008 Mar 12	18317009
Inflammation, insulin resistance, and type 2 diabetes: back to the future?	2009 Feb	19171748
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.	2009 Jan	18835953
Serum concentration-dependent hepatotoxicity in individuals receiving oral salsalate.	2009 Jun	18770032
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.	2009 Mar	19104769
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.	2009 Mar 10	19237660
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009 Oct 2	19798416
Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice.	2010	21403905
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts.	2010 Jul	20587709
Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.	2010 Jul 31	20613460
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.	2010 Mar 16	20231565
Summaries for patients. The effects of salsalate on blood sugar control in people with type 2 diabetes.	2010 Mar 16	20231550
The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects.	2010 Nov	22043213
An overview of salsalate as a potential antidiabetic therapy.	2010 Nov	21225023
A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease.	2010 Nov	20713682
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.	2010 Sep	20080359

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:41:25 GMT 2025` Edited by `admin` on `Mon Mar 31 23:41:25 GMT 2025`
Record UNII	06SH0H2G8M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SALSALATE SODIUM

Common Name

English

2-HYDROXYBENZOIC ACID 2-CARBOXYPHENYL ESTER SODIUM SALT

Preferred Name

English

SODIUM SALICYLSALICYLATE

Systematic Name

English

BENZOIC ACID, 2-HYDROXY-, 2-CARBOXYPHENYL ESTER, MONOSODIUM SALT

Systematic Name

English

Code System Code Type Description

FDA UNII

06SH0H2G8M

Created by admin on Mon Mar 31 23:41:25 GMT 2025 , Edited by admin on Mon Mar 31 23:41:25 GMT 2025

PRIMARY

PUBCHEM

23662396

Created by admin on Mon Mar 31 23:41:25 GMT 2025 , Edited by admin on Mon Mar 31 23:41:25 GMT 2025

PRIMARY

EPA CompTox

DTXSID40178111

Created by admin on Mon Mar 31 23:41:25 GMT 2025 , Edited by admin on Mon Mar 31 23:41:25 GMT 2025

PRIMARY

CAS

23520-54-9

Created by admin on Mon Mar 31 23:41:25 GMT 2025 , Edited by admin on Mon Mar 31 23:41:25 GMT 2025

PRIMARY

Related Record Type Details


					V9MO595C9I

SALSALATE

PARENT -> SALT/SOLVATE

Related Record Type Details


					V9MO595C9I

SALSALATE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.drugs.com/pro/salsalate.htmlCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23817699 | https://www.ncbi.nlm.nih.gov/pubmed/6520777

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.drugs.com/pro/salsalate.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23817699 | https://www.ncbi.nlm.nih.gov/pubmed/6520777

C_max

T_1/2

F_unbound

Drug as perpetrator